Apomorphine pharmacokinetic-pharmacodynamic correlations following single and repeated subcutaneous injections in patients with Parkinson's disease

被引：0
|
作者：
Bottini, PB
Shaw, A
Huang, MY
Sherry, JH
机构：
来源：
MOVEMENT DISORDERS | 2002年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P293
引用
收藏
页码：S101 / S101
页数：1
相关论文
共 50 条
  • [31] Subcutaneous apomorphine injections for advanced Parkinson's disease: a long-term follow-up
    Athanasopoulos, D.
    Tagaris, G. A.
    Karageorgiou, C. E.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 655 - 655
  • [32] Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease
    Pfeiffer, Ronald F.
    Gutmann, Ludwig
    Hull, Keith L., Jr.
    Bottini, Peter B.
    Sherry, James H.
    PARKINSONISM & RELATED DISORDERS, 2007, 13 (02) : 93 - 100
  • [33] The pharmacokinetic and clinical effects of tolcapone on a single dose of sublingual apomorphine in Parkinson's disease
    Ondo, WG
    Hunter, C
    Vuong, KD
    Jankovic, J
    PARKINSONISM & RELATED DISORDERS, 2000, 6 (04) : 237 - 240
  • [34] Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease
    Hellmann, Mark A.
    Sabach, Tilda
    Melamed, Eldad
    Djaldetti, Ruth
    BIOMEDICINE & PHARMACOTHERAPY, 2008, 62 (04) : 250 - 252
  • [35] A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease
    Chen, JJ
    Obering, C
    CLINICAL THERAPEUTICS, 2005, 27 (11) : 1710 - 1724
  • [36] Population pharmacokinetic pharmacodynamic modeling of istradefylline in patients with Parkinson's disease.
    Knebel, W.
    Rao, N.
    Bergsma, T.
    Gastonguay, M.
    Mori, A.
    Uchimura, T.
    Allenby, K.
    Dvorchik, B.
    Sussman, N.
    Chaikin, P.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 47 (09): : 1185 - 1185
  • [37] Levodopa pharmacokinetic-pharmacodynamic modeling and 6-[18F]levodopa positron emission tomography in patients with Parkinson's disease
    Dietz, M
    Harder, S
    Graff, J
    Künig, G
    Vontobel, P
    Leenders, KL
    Baas, H
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 70 (01) : 33 - 41
  • [38] A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study
    Nomoto, Masahiro
    Kubo, Shin-ichiro
    Nagai, Masahiro
    Yamada, Tatsuo
    Tamaoka, Akira
    Tsuboi, Yoshio
    Hattori, Nobutaka
    CLINICAL NEUROPHARMACOLOGY, 2015, 38 (06) : 241 - 247
  • [39] Decrease in UPDRS motor scores following intermittent subcutaneous apomorphine for 6 months in patients with advanced Parkinson's disease
    Trosch, DM
    MOVEMENT DISORDERS, 2004, 19 : S217 - S217
  • [40] Continued effect of intermittent subcutaneous apomorphine following long-term use in patients with advanced Parkinson's disease
    Pfeiffer, DF
    MOVEMENT DISORDERS, 2004, 19 : S281 - S282
12345